These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 36900378)
21. Ma G; Liu C; Lian W; Zhang Y; Yuan H; Zhang Y; Song S; Yang Z Ann Nucl Med; 2021 May; 35(5):600-607. PubMed ID: 33689138 [TBL] [Abstract][Full Text] [Related]
22. EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer. Yardley DA; Weaver R; Melisko ME; Saleh MN; Arena FP; Forero A; Cigler T; Stopeck A; Citrin D; Oliff I; Bechhold R; Loutfi R; Garcia AA; Cruickshank S; Crowley E; Green J; Hawthorne T; Yellin MJ; Davis TA; Vahdat LT J Clin Oncol; 2015 May; 33(14):1609-19. PubMed ID: 25847941 [TBL] [Abstract][Full Text] [Related]
24. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Rose AA; Grosset AA; Dong Z; Russo C; Macdonald PA; Bertos NR; St-Pierre Y; Simantov R; Hallett M; Park M; Gaboury L; Siegel PM Clin Cancer Res; 2010 Apr; 16(7):2147-56. PubMed ID: 20215530 [TBL] [Abstract][Full Text] [Related]
25. ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer. Chen W; Li M; Younis MH; Barnhart TE; Jiang D; Sun T; Lang JM; Engle JW; Zhou M; Cai W Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):861-870. PubMed ID: 34519889 [TBL] [Abstract][Full Text] [Related]
26. Pool M; Kol A; de Jong S; de Vries EGE; Lub-de Hooge MN; Terwisscha van Scheltinga AGT MAbs; 2017; 9(8):1370-1378. PubMed ID: 28873009 [TBL] [Abstract][Full Text] [Related]
28. Therapeutic Response Monitoring with Kang M; Shin JI; Han S; Kim JY; Park J; Kim KI; Kang JH; Lee TS Pharmaceutics; 2022 Jun; 14(7):. PubMed ID: 35890234 [TBL] [Abstract][Full Text] [Related]
29. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305 [TBL] [Abstract][Full Text] [Related]
30. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer. Bendell J; Saleh M; Rose AA; Siegel PM; Hart L; Sirpal S; Jones S; Green J; Crowley E; Simantov R; Keler T; Davis T; Vahdat L J Clin Oncol; 2014 Nov; 32(32):3619-25. PubMed ID: 25267761 [TBL] [Abstract][Full Text] [Related]
31. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. Holland JP; Caldas-Lopes E; Divilov V; Longo VA; Taldone T; Zatorska D; Chiosis G; Lewis JS PLoS One; 2010 Jan; 5(1):e8859. PubMed ID: 20111600 [TBL] [Abstract][Full Text] [Related]
32. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin. Biondini M; Kiepas A; El-Houjeiri L; Annis MG; Hsu BE; Fortier AM; Morin G; Martina JA; Sirois I; Aguilar-Mahecha A; Gruosso T; McGuirk S; Rose AAN; Tokat UM; Johnson RM; Sahin O; Bareke E; St-Pierre J; Park M; Basik M; Majewski J; Puertollano R; Pause A; Huang S; Keler T; Siegel PM Oncogene; 2022 Mar; 41(12):1701-1717. PubMed ID: 35110681 [TBL] [Abstract][Full Text] [Related]
33. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab. Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647 [TBL] [Abstract][Full Text] [Related]
34. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Kolb EA; Gorlick R; Billups CA; Hawthorne T; Kurmasheva RT; Houghton PJ; Smith MA Pediatr Blood Cancer; 2014 Oct; 61(10):1816-21. PubMed ID: 24912408 [TBL] [Abstract][Full Text] [Related]
35. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. Holland JP; Divilov V; Bander NH; Smith-Jones PM; Larson SM; Lewis JS J Nucl Med; 2010 Aug; 51(8):1293-300. PubMed ID: 20660376 [TBL] [Abstract][Full Text] [Related]
36. Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer. Terwisscha van Scheltinga AG; Berghuis P; Nienhuis HH; Timmer-Bosscha H; Pot L; Gaykema SB; Lub-de Hooge MN; Kosterink JG; de Vries EG; Schröder CP Eur J Cancer; 2014 Sep; 50(14):2508-16. PubMed ID: 25027745 [TBL] [Abstract][Full Text] [Related]
39. Dasatinib prevents skeletal metastasis of osteotropic MDA-MB-231 cells in a xenograft mouse model. Heilmann T; Rumpf AL; Roscher M; Tietgen M; Will O; Gerle M; Damm T; Borzikowsky C; Maass N; Glüer CC; Tiwari S; Trauzold A; Schem C Arch Gynecol Obstet; 2020 Jun; 301(6):1493-1502. PubMed ID: 32170411 [TBL] [Abstract][Full Text] [Related]
40. A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts. Paquette M; Phoenix S; Lawson C; Guérin B; Lecomte R; Tai LH; Turcotte ÉE; Leyton JV EJNMMI Res; 2020 Jun; 10(1):69. PubMed ID: 32592121 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]